Physician profile
David B Mainman
NPI 1669458840
$1,395.66
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $384 · 2021: $305 · 2022: $290 · 2023: $23.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.91 | 2019-2022 | |
| Hologic Sales and Service, LLC | $236.56 | 2019-2022 | |
| Abbott Laboratories | $118.34 | 2021-2023 | Proclaim |
| Allergan, INC. | $107.39 | 2019-2020 | |
| Therapeuticsmd, INC. | $85.33 | 2019-2022 | |
| Myovant Sciences INC. | $82.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.96 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.78 | 2019-2021 | |
| Exeltis, USA INC. | $56.50 | 2019-2022 | |
| Aspira Women'S Health INC | $42.14 | 2021 | |
| Organon LLC | $41.97 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $39.96 | 2019-2020 | |
| Davol INC. | $25.30 | 2021 | |
| Mallinckrodt Enterprises LLC | $23.70 | 2019 | |
| Roche Diagnostics Corporation | $22.27 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $22.08 | 2019 | |
| Lupin INC. | $17.85 | 2019 | |
| Conmed Corporation | $16.45 | 2019 | |
| Astellas Pharma US INC | $14.00 | 2022 | |
| Evofem Biosciences, INC. | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mainman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.